Furthermore, Tsubaki, M. et al., demonstrated that inhibition of ERK1/2 and Akt inhibits the expression of angiogenic factors in osteosarcoma cells, which thus suggests the use of statins as potential anti-angiogenic agents for the treatment of osteosarcoma [154]. Here, MAPK3 is linked to osteosarcoma.